Modulation of innate immunological factors by STEALTH liposome-encapsulated tumor necrosis factor-alpha in a colon tumor xenograft model. 2002

Dong W Kim, and Melba L Andres, and Eric H Kajioka, and Radha Dutta-Roy, and Glen M Miller, and Ann L B Seynhaeve, and Timo L M ten Hagen, and Daila S Gridley
Department of Radiation Medicine, Loma Linda University and Medical Center, CA 92354, USA. dkim03mz@som.llu.edu

BACKGROUND Previous studies have shown that tumor necrosis factor-alpha (TNF-alpha) encapsulated in sterically-stabilized PEGylated STEALTH liposomes (SL) can better and more safely augment the efficacy of other treatment modalities than free TNF-alpha. The aim of this study was to examine the effects of SL-TNF-alpha in the LS174T human colon tumor xenograft model and to correlate its administration with alterations in innate immune system parameters. METHODS Nude mice (n = 128) were injected subcutaneously with LSI 74T cells and treated intravenously with SL-TNF-alpha SL-placebo, or free recombinant human TNF-alpha; the animals were euthanized at 6, 18, 36 and 96 hours after injection. RESULTS Significant increases in leukocyte, granulocyte, monocyte and NK cell numbers were observed early (6 hours) in the blood from both SL-TNF-alpha and free TNF-alpha treated mice compared to the control group. In contrast, during the 18- to 36-hours interval, SL-TNF-alpha induced significantly higher (p<0.05) leukoctyte, T cell, and NK cell numbers, basal leukocyte proliferation, and CD25+ activation marker expression; the modulation occurred primarily in the spleen. CONCLUSIONS These data indicate that both SL-TNF-alpha and free TNF-alpha can induce dramatic up-regulation in leukocyte populations early after injection. However, the up-regulation produced by SL-TNF-alpha was more prolonged and pronounced than that of TNF-alpha and had better correlation with cell activation. These findings suggest that sustained leukocyte recruitment and/or activation may be an important factor in the greater than additive or synergistic antitumor effects observed when SL-TNF-alpha is used in combination with other cancer therapies.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008297 Male Males
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

Dong W Kim, and Melba L Andres, and Eric H Kajioka, and Radha Dutta-Roy, and Glen M Miller, and Ann L B Seynhaeve, and Timo L M ten Hagen, and Daila S Gridley
March 1997, Critical care medicine,
Dong W Kim, and Melba L Andres, and Eric H Kajioka, and Radha Dutta-Roy, and Glen M Miller, and Ann L B Seynhaeve, and Timo L M ten Hagen, and Daila S Gridley
December 1990, International journal of cancer,
Dong W Kim, and Melba L Andres, and Eric H Kajioka, and Radha Dutta-Roy, and Glen M Miller, and Ann L B Seynhaeve, and Timo L M ten Hagen, and Daila S Gridley
January 1990, Cancer research,
Dong W Kim, and Melba L Andres, and Eric H Kajioka, and Radha Dutta-Roy, and Glen M Miller, and Ann L B Seynhaeve, and Timo L M ten Hagen, and Daila S Gridley
December 2000, Clinical cancer research : an official journal of the American Association for Cancer Research,
Dong W Kim, and Melba L Andres, and Eric H Kajioka, and Radha Dutta-Roy, and Glen M Miller, and Ann L B Seynhaeve, and Timo L M ten Hagen, and Daila S Gridley
December 1992, Journal of leukocyte biology,
Dong W Kim, and Melba L Andres, and Eric H Kajioka, and Radha Dutta-Roy, and Glen M Miller, and Ann L B Seynhaeve, and Timo L M ten Hagen, and Daila S Gridley
January 1988, Haematologica,
Dong W Kim, and Melba L Andres, and Eric H Kajioka, and Radha Dutta-Roy, and Glen M Miller, and Ann L B Seynhaeve, and Timo L M ten Hagen, and Daila S Gridley
January 1999, Advances in experimental medicine and biology,
Dong W Kim, and Melba L Andres, and Eric H Kajioka, and Radha Dutta-Roy, and Glen M Miller, and Ann L B Seynhaeve, and Timo L M ten Hagen, and Daila S Gridley
June 2001, Biological & pharmaceutical bulletin,
Dong W Kim, and Melba L Andres, and Eric H Kajioka, and Radha Dutta-Roy, and Glen M Miller, and Ann L B Seynhaeve, and Timo L M ten Hagen, and Daila S Gridley
November 1990, The Journal of clinical endocrinology and metabolism,
Dong W Kim, and Melba L Andres, and Eric H Kajioka, and Radha Dutta-Roy, and Glen M Miller, and Ann L B Seynhaeve, and Timo L M ten Hagen, and Daila S Gridley
November 2004, Yao xue xue bao = Acta pharmaceutica Sinica,
Copied contents to your clipboard!